Investigating the effects of HGR4113 in healthy adults

A Randomized, Double-Blind, Placebo Controlled, Single and Multiple Dosing, Dose-Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect After Oral Administration of HGR4113 in Healthy Subjects

This study is testing a new drug called HGR4113 in healthy adults to see if it's safe and how it works in the body after taking it in different amounts.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 19 Years to 50 Years
• Sex: All
• Sponsor: Glaceum (industry)
• Locations: 1 site (Seoul)
• Trial ID: NCT05642377 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of HGR4113 after single and multiple oral doses in healthy subjects. It employs a randomized, double-blind, placebo-controlled design, where participants are assigned to receive either the active drug or a placebo. The study will escalate doses based on safety data collected during the trial, with assessments including vital signs and ECGs to monitor health outcomes.

Who should consider this trial

Good fit: Ideal candidates are healthy adults aged 19 to 50 with a BMI between 18.0 and 24.9.

Not a fit: Patients with significant medical histories or conditions affecting the liver, kidneys, or other major systems may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to a better understanding of HGR4113's effects, potentially paving the way for new treatments for Type 2 Diabetes Mellitus.

How similar studies have performed: While this approach is common in early-phase trials, the specific drug HGR4113 has not been previously tested in this manner.

Eligibility criteria

Inclusion Criteria:

1. Able to comprehend and willing to sign an informed consent form approved by the IRB before Screening.
2. Adult volunteers between 19 and 50 years of age at Screening.
3. Body mass index (BMI) between 18.0 and 24.9.

   ☞ BMI (kg/m\^2) = body weight (kg) / (height \[m\])\^2
4. In good health, determined by no clinically significant findings from medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory tests at Screening, or subjects who are deemed acceptable by the Investigator regardless of the test results.

Exclusion Criteria:

1. Significant history or clinical manifestation of any hepatic, kidney, neurological, immune, respiratory, endocrine, hematological, neoplastic, or cardiovascular disease, or psychiatric disorder (e.g., mood disorder, obsessive-compulsive disorder).
2. History of stomach or intestinal disorders (e.g., Chron's disease, ulcer) or surgeries - not including appendectomy, hemorrhoidectomy, or herniotomy - which may affect the safety or pharmacokinetic/pharmacodynamic evaluation of the investigational product.
3. Significant history or clinical manifestation of hypersensitivity to any drug including licorice or other drug (e.g., aspirin, antibiotics).
4. One or more of the following laboratory test results at Screening:

   * ANC \< 1000
   * AST, ALT, GGT, total bilirubin \> 1.5x upper limit normal
   * Fasting glucose ≥ 126 mg/dL or HbA1c ≥ 6.5% despite two retests
   * eGFR \< 60 (CKD-EPI).
5. Systolic blood pressure \< 90 mmHg or \> 150 mmHg, or diastolic blood pressure \< 60 mgHg or \> 100 mmHg as determined by vital signs monitored after resting in sitting position for at least 3 minutes.
6. History of drug/chemical abuse or tested positive in urine drug screen.
7. Used or intend to use any prescription medications/products or phytotherapeutic/herbal/plant-derived preparations within 14 days prior to dosing, or any nonprescription medications/products (i.e., over-the-counter (OTC) drugs), health products, or vitamins within 7 days prior to dosing, unless deemed acceptable by the Investigator.
8. Participation in any clinical study or bioequivalence study within 6 months prior to dosing.
9. Whole blood donation within 2 months prior to dosing, plasma/platelet donation within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing.
10. Alcohol consumption \> 21 units/week (1 unit = 10 g of pure alcohol) or unable to abstain from consuming alcohol 3 days prior to first dosing until the last pharmacokinetic blood sampling.
11. History of smoking within 90 days prior to dosing (however, participation is acceptable if the subject has quit at least 90 days prior to dosing) or unable to abstain from smoking 90 days prior to dosing until the last pharmacokinetic blood sampling.
12. Ingestion of grapefruit-containing foods or beverages 24 hours 3 days prior to dosing until the last pharmacokinetic blood sampling, or unable to abstain from ingesting such foods or beverages during the same period.
13. Unable to abstain from ingesting caffeine-containing foods or beverages (e.g., coffee, tea \[e.g., black tea, green tea\], soft drinks, coffee milk, energy drinks, sports drinks) 3 days prior to dosing until the last pharmacokinetic blood sampling.
14. Females, excluding those who have amenorrhea for at least 12 months or have been surgically sterilized (e.g., bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), who are pregnant or lactating, evidenced by a positive urine hCG pregnancy test.
15. Subject or subject's partner is unable or unwilling to use a medically acceptable means of contraception during and for 90 days following the last dosing or willing to donate sperm during the same period.

    - Acceptable contraceptive methods include:
    * Use of an intrauterine device that has been proven highly effective
    * Male or female physical contraceptive used with chemical sterilization
    * Surgical sterilization of the subject or the subject's partner (e.g., vasectomy, hysterectomy, tubal ligation, salpingectomy).
16. Subjects who, in the opinion of the Investigator, should not participate in in this study based on other reasons.
17. Subject who is confirmed as the CYP2C19 poor metabolizer (e.g., \*2/\*2, \*2/\*3, \*3/\*3) by exploratory genotyping test at Screening in MAD group.

Where this trial is running

Seoul

• Seoul National University Hospital — Seoul, Korea, Republic of (RECRUITING)

Study contacts

• Principal investigator: Kyung Sang Yu, MD, PhD — Seoul National University Hospital
• Study coordinator: Youngah Kim

Conditions: Diabetes Mellitus, Type 2